[1] Kohan AB. Apolipoprotein C-III:a potent modulator of hypertriglyceridemia and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes, 2015; 22, 119-25. doi:  10.1097/MED.0000000000000136
[2] Mahley RW, Innerarity TL, Rall SC Jr, et al. Plasma lipoproteins:apolipoprotein structure and function. J Lipid Res, 1984; 25, 1277-94.
[3] Sundaram M, Zhong S, Bou Khalil M, et al. Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J Lipid Res, 2010; 51, 150-61. doi:  10.1194/M900346-JLR200
[4] Wang F, Kohan AB, Dong HH, et al. Overexpression of apolipoprotein C-III decreases secretion of dietary triglyceride into lymph. Physiol Rep, 2014; 2, e00247. https://www.researchgate.net/publication/260532130_Overexpression_of_apolipoprotein_C-III_decreases_secretion_of_dietary_triglyceride_into_lymph
[5] Kawakami A, Aikawa M, Alcaide P, et al. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation, 2006; 114, 681-7. doi:  10.1161/CIRCULATIONAHA.106.622514
[6] Crosby J, Peloso GM, Auer PL, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. New Engl J Med, 2014; 371, 22-31. doi:  10.1056/NEJMoa1307095
[7] Qamar A, Khetarpal SA, Khera AV, et al. Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics. Arterioscler Thromb Vasc Biol, 2015; 35, 1880-8. doi:  10.1161/ATVBAHA.115.305415
[8] Hokanson JE, Kinney GL, Cheng S, et al. Susceptibility to type 1 diabetes is associated with ApoCIII gene haplotypes. Diabetes, 2006; 55, 834-8. doi:  10.2337/diabetes.55.03.06.db05-1380
[9] Caron S, Verrijken A, Mertens I, et al. Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol, 2011; 31, 513-9. doi:  10.1161/ATVBAHA.110.220723
[10] Holmberg R, Refai E, Hoog A, et al. Lowering apolipoprotein CIII delays onset of type 1 diabetes. Proc Natl Acad Sci USA, 2011; 108, 10685-9. doi:  10.1073/pnas.1019553108
[11] Li AH, Morrison AC, Kovar C, et al. Analysis of loss-of-function variants and 20 risk factor phenotypes in 8,554 individuals identifies loci influencing chronic disease. Nat Genet, 2015; 47, 640-2. doi:  10.1038/ng.3270
[12] Welty FK, Alfaddagh A, Elajami TK. Targeting inflammation in metabolic syndrome. Transl Res, 2016; 167, 257-80. doi:  10.1016/j.trsl.2015.06.017
[13] Mori N, McEvoy JP, Miller BJ. Total and differential white blood cell counts, inflammatory markers, adipokines, and the metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Schizophr Res, 2015; 169, 30-5. doi:  10.1016/j.schres.2015.10.001
[14] Zimmet P, KG MMA, Serrano Rios M. A new international diabetes federation worldwide definition of the metabolic syndrome:the rationale and the results. Rev Esp Cardiol, 2005; 58, 1371-6. doi:  10.1016/S0300-8932(05)74065-3
[15] Balkau B, Eschwege E. The metabolic syndrome. Lancet, 2005; 366, 1921. doi:  10.1016/S0140-6736(05)67778-1
[16] Bays HE, Jones PH, Brown WV, et al. National Lipid Association Annual Summary of Clinical Lipidology [2015] J Clin Lipidol, 2014; 8, S1-36. https://www.researchgate.net/profile/Peter_Jones32/publication/295099132_National_Lipid_Association_Annual_Summary_of_Clinical_Lipidology_2016/links/56cb14ce08ae5488f0dadd34.pdf?origin=publication_detail
[17] Li S, Zhang Y, Xu RX, et al. Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease. Ann Med, 2015; 47, 386-93. doi:  10.3109/07853890.2015.1042908
[18] Zheng C, Azcutia V, Aikawa E, et al. Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion. Eur Heart J, 2013; 34, 615-24. doi:  10.1093/eurheartj/ehs271
[19] Liu Y, Wu M, Ling J, et al. Serum IGFBP7 levels associate with insulin resistance and the risk of metabolic syndrome in a Chinese population. Sci Rep, 2015; 5, 10227. doi:  10.1038/srep10227
[20] Solymoss BC, Bourassa MG, Campeau L, et al. Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am J Cardiol, 2004; 93, 159-64. doi:  10.1016/j.amjcard.2003.09.032
[21] Eberly LE, Prineas R, Cohen JD, et al. Metabolic syndrome:risk factor distribution and 18-year mortality in the multiple risk factor intervention trial. Diabetes Care, 2006; 29, 123-30. doi:  10.2337/diacare.29.01.06.dc05-1320
[22] Wang CS, McConathy WJ, Kloer HU, et al. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest, 1985; 75, 384-90. doi:  10.1172/JCI111711
[23] Meikle PJ, Christopher MJ. Lipidomics is providing new insight into the metabolic syndrome and its sequelae. Curr Opin Lipidol, 2011; 22, 210-5. doi:  10.1097/MOL.0b013e3283453dbe
[24] Stefan N, Haring HU, Hu FB, et al. Metabolically healthy obesity:epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol, 2013; 1, 152-62. doi:  10.1016/S2213-8587(13)70062-7